domingo, 2 de octubre de 2011

Prime Minister Recognises Cancer As A National Health Priority: Cancerbackup Welcomes Cuts On Waiting Times, UK

In response to Prime Minister Gordon Brown's speech, Cancerbackup issues the following statement:


"The Prime Minister has shown today that cancer is one of his absolute priorities," says Joanne Rule Cancerbackup Chief Executive. "It is vital that treatment for cancer is started as soon as possible to ensure the best chance of survival, which is why we welcome today's announcements to reduce cancer waiting times and particularly treat all breast cancer cases as urgent.


"We know from a MORI poll carried out for Cancerbackup last year, that 76 per cent of the public believe that cancer is a national health priority, placing it way ahead of other illnesses. What we need now is for the Cancer Reform Strategy to be published soon and for it to include real targets."


Results of Cancerbackup's Ipsos MORI poll on cancer priorities


1. Cancerbackup is the only national charity that specialises in providing information on all types of cancer.


2. All Cancerbackup services are free to cancer patients, their relatives and friends.


3. Cancerbackup Freephone Information Service: 0808 800 1234 (Mon-Fri, 9am-8pm). Cancerbackup Centres can be found in St Bartholomew's Hospital, Charing Cross Hospital, the London Clinic, The Christie Hospital, Ipswich Hospital, Nottingham City Hospital, Coventry's University Hospital and Jersey. The charity's website can be found at cancerbackup


4. Cancerbackup, as a charity, receives 54% of its funding from individuals, 11% from charitable trusts, 5% from grants, 14% from companies, 2% from investments and 14% from its trading company. Pharmaceutical companies contributed 9% of the total 2005/06 income.


5. In April 2006 Cancerbackup changed its name from CancerBACUP, so that the charity's name better represents the service the charity provides: information, understanding and support to anyone affected by cancer.


cancerbackup

Our Recommendations:


•   Buy Robaxin
•   Purchase Yaz Online
•   Purchase Nexium Online
•   Buy Atripla Online

Peptimmune Completes Phase I Study With A Novel Peptide Copolymer For The Treatment Of Multiple Sclerosis

Peptimmune, Inc. a privately
held biotechnology company, announced that it has completed its first
clinical trial to evaluate the safety, tolerability, pharmacokinetics and
pharmacodynamics of PI-2301, a novel peptide copolymer for the treatment of
multiple sclerosis and other autoimmune diseases.


The Phase I single ascending dose, double blind placebo controlled
randomized study involved 56 healthy volunteers who received the drug in
eight escalating dose cohorts. All doses were safe and well tolerated, and
there were no serious adverse events. Pharmacodynamic assays demonstrated
evidence of immune exposure consistent with the pharmacologic mechanism of
action for PI-2301, and dose related pharmacokinetics were observed. The
Company plans to initiate its first repeat dose study in multiple sclerosis
patients in Q2/2008.



"We are pleased to see that PI-2301 was well tolerated and that this
trial has provided evidence of single dose priming of healthy subjects.
This effect is important as repeated doses in multiple sclerosis patients
should lead to therapeutic immune modulation," stated Thomas P. Mathers,
President and CEO of Peptimmune. "We have designed PI-2301 to maximize the
therapeutic benefit of a proven, safe compound class in multiple sclerosis
as well as increasing patients' convenience."



PI-2301 is a second generation peptide copolymer from a similar
compound class as Copaxone(R) (Teva Pharmaceuticals). PI-2301 works through
immune modulation by enhancing the regulatory response of the immune system
to control the pathogenic autoimmune response in certain diseases. PI-2301
has been optimized using Peptimmune's novel platform peptide chemistry and
in pre- clinical studies, has shown to be more potent and effective than
Copaxone in treating disease models for multiple sclerosis. PI-2301 has
also shown efficacy in pre-clinical models of autoimmune diseases where
immune modulation may be effective, such as Crohn's disease, rheumatoid
arthritis and autoimmune uveitis. Peptimmune has also introduced highly
reproducible manufacturing methods that allow very strict control and
characterization of PI-2301 and should provide a superior level of batch to
batch consistency.



Over 400,000 Americans have multiple sclerosis (MS), and worldwide MS
may affect over 2.5 million individuals. MS is an autoimmune disease in
which the individuals' immune system responds against multiple components
of nerve- insulating myelin. The effects of these immune-mediated attacks
can range from relatively benign to somewhat disabling to devastating, as
communication between the brain and other parts of the body is disrupted.



About Peptimmune



Peptimmune, Inc. is a privately held clinical stage biotechnology
company focused on the development of peptide therapies to improve the
management of chronic autoimmune and inflammatory disorders. The Company is
in clinical development with second-generation therapeutics that are
expected to result in safer and more effective products for multiple
sclerosis and pemphigus vulgaris. Current investors include New Enterprise
Associates, MPM Capital, Hunt Ventures, Boston Medical Investors, Silicon
Valley Bank Capital, and Genzyme Corporation. For additional information,
access our website at peptimmune.


Peptimmune, Inc.

peptimmune



View drug information on Copaxone.

Our Recommendations:


•   Purchase Elavil Online
•   Order Yaz No Prescription
•   Buy Trileptal Online No Prescription
•   Purchase Ortho Tri-Cyclen
•   Purchase Aciphex Online

Structure Of DNA Repair Complex Reveals Workings Of Powerful Cell Motor

Over the last years, two teams of researchers at The Scripps Research Institute have steadily built a model of how a powerful DNA repair complex works. Now, their latest discovery provides revolutionary insights into the way the molecular motor inside the complex functions - findings they say may have implications for treatment of disorders ranging from cancer to cystic fibrosis.



In a paper published in an Advance Online Edition of Nature Structural and Molecular Biology March 27, 2011, the scientists say that the complex's motor molecule, known as Rad50, is a surprisingly flexible protein that can change shape and even rotate depending on the task at hand.



The finding solves the long-standing mystery of how a single protein complex known as MRN (Mre11-Rad50-Nbs1) can repair DNA in a number of different, and tricky, ways that seem impossible for "standard issue" proteins to do, say team leaders Scripps Research Professor John Tainer, Ph.D., and Scripps Research Professor Paul Russell, Ph.D., who also collaborated with members of the Lawrence Berkeley National Laboratory on the study.



They say the finding also provides a critical insight into the ABC-ATPase superfamily of molecular motors, of which Rad50 is a member.



"Rad50 and its brethren proteins in this superfamily are biology's general motors," said Tainer, "and if we know how they work, we might be able to control biological outcomes when we need to."



For example, knowing that Rad50 changes its contour to perform a function suggests it might be possible to therapeutically target unique elements in that specific conformation. "There could be a new generation of drugs that are designed not against an active site, like most drugs now (an approach that can cause side effects, but against the shape the protein needs to be in to work," Tainer said.



Russell added, "Proteins are often viewed as static, but we are showing the moving parts in this complex. They are dynamic. They move about and change shape when engaging with other molecules."



First Responder



The MRN complex is known as a first-responder molecule that rushes in to repair serious double-strand breaks in the DNA helix - an event that normally occurs about 10 times a day per cell due to ultraviolet light and radiation damage, etc. If these breaks are not fixed, dangerous chromosomal rearrangements can occur that lead to cancer. Paradoxically, the complex also mends DNA breaks promoted by chemotherapy, protecting cells against cancer treatment.



When MRN senses a break, it activates an alarm telling the cell to shut down division until repairs are made. Then, it binds to ATP (an energy source) and repairs DNA in three different ways, depending on whether two ends of strands need to be joined together or if DNA sequences need to be replicated. "The same complex has to decide the extent of damage and be able to do multiple things," Tainer said. "The mystery was how it can do it all."
















To find out, Tainer, head of a structural biology group, and Russell, who leads a yeast genetics laboratory, began collaborating five years ago. With the additional help of team members at Lawrence Berkeley National Laboratory and its Advanced Light Source beamline, called SIBYLS, the collaboration has produced a series of high-resolution images of the crystal structure of parts of all three proteins (rad50, Mre11, and Nbs1), taken from fission yeast and archaea. The scientists also used the lab's X-ray scattering tool to determine the proteins' overall architecture in solution, which approximates how a protein appears in a natural state.



The scientists say that the parts of the complex, when imagined together as a whole unit, resemble an octopus: the head consists of the repair machinery (the Rad50 motor and the Mre11 protein, which is an enzyme that can break bonds between nucleic acids) and the octopus arms are made up of Nbs1 which can grab the molecules needed to help the machinery mend the strands.



In this study, Tainer and Russell were able to produce crystal and X-ray scattering images of parts of where Rad50 and Mre11 touched each other, and what happened when ATP bound to this complex and what it looked like when it didn't.



In these four new structures, they showed that ATP binding allows Rad50 to drastically change its shape. When not bound to ATP, Rad50 is flexible and floppy, but bound to ATP, Rad50 snaps into a ring that presumably closes around DNA in order to repair it.



"We saw a lot of big movement on a molecular scale," said Tainer. "Rad50 is like a rope that can pull. It appears to be a dynamic system of communicating with other molecules, and so we can now see how flexibly linked proteins can alter their physical states to control outcomes in biology."



"We thought ATP allowed Rad50 to change shape, but now we have proof of it and how it works," Russell said. "This is a key part of the MRN puzzle."



An Engine for Many Vehicles



Rad50 and ATP provide the motor and gas for a number of biological machines that operate across species. These machines are linked to a number of disorders, such as cystic fibrosis, which is caused by a defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which is a member of the ABC ATPase superfamily.



"Our study suggests that ABC ATPase proteins are used so often in biology because they can flexibly hook up to so many different things and produce a specific biological outcome," Tainer said.



Given this new prototypic understanding of these motors, Tainer and Russell envision a future in which therapies might be designed that target Rad50 when it changes into a shape that promotes a disease. For example, chemotherapy could be coupled with an agent that prevents the MRN complex from repairing DNA damage, promoting death of cancer cells.



"There are some potentially very cool applications to these findings that we are only beginning to think about," Russell said.


Notes:


Co-authors of the paper, "ABC ATPase signature helices in Rad50 link nucleotide state to Mre11 interface for DNA repair," include Gareth J. Williams, Soumita SilDas, and Michal Hammel of the Lawrence Berkeley National Laboratory; and R. Scott Williams, Jessica S. Williams, Gabriel Moncalian, Andy Arval, Oliver Limbo, and Grant Guenther of The Scripps Research Institute.



The study was funded by the National Cancer Institute, the National Institutes of Health, and the Department of Energy.



Our Recommendations:


•   Purchase Sterapred No Prescription
•   Buy Cheap Armour
•   Retin-A Purchase
•   Buy Cheap Imitrex
•   Buy Cheap Naltrexone

Researchers At HIV/AIDS Vaccine Conference Discuss New Methods, Ongoing Trials

Researchers at the AIDS Vaccine 2008 conference in Cape Town, South Africa, last week examined how setbacks in developing a vaccine have "forced them to look for entirely new ways of creating a defense against the disease," AFP/Google reports. "We are in the middle of quite a profound shift of mindset in the research community," Alan Bernstein, director of the Global HIV Vaccine Enterprise, said at the conference, which ended on Friday. He added that setbacks have made researchers examine new research methods in the effort to develop an HIV/AIDS vaccine (Blandy, AFP/Google, 10/18).

Merck in September 2007 announced it had halted a large-scale clinical trial of its experimental HIV vaccine after the drug failed to prevent HIV infection in participants or prove effective in delaying the virus' progression to AIDS. The vaccine candidate also might have put some trial participants at an increased risk of HIV. Following news of the Merck vaccine, trials of NIH's Vaccine Research Center's HIV vaccine candidate were scaled back (Kaiser Daily HIV/AIDS Report, 10/16).

"The Merck result was such a surprise, and everyone was kind of shocked off their horses," Mitchell Warren of the AIDS Vaccine Advocacy Coalition said, adding, "What happened, no one could have predicted. They still don't understand exactly what happened. That finding forces people to realign and look at new ways and new approaches to how we are going to find an AIDS vaccine because it was so surprising." According to Warren, the results of the Merck trial have made researchers rethink assumptions about how vaccines work. "People are really grappling with new ways of doing things," he said.

About 30 clinical trials for vaccine candidates are under way worldwide, and the "most watched" is a study in Thailand that began in 2003, according to AFP/Google. Results from the trial are expected next year, and about 16,000 people are participating. According to some researchers, the trial will provide important information about HIV/AIDS whatever its outcome.

According to Bernstein, the most interesting new research into HIV/AIDS vaccines involves defenses in the body called the innate immune system. The innate immune system serves as an "early warning system for invading diseases," AFP/Google reports, and Bernstein said that the system could stop HIV if researchers determine a method of triggering it early. "We now know we may have only hours, at most days, before we have a window of opportunity to stop HIV," he said, adding, "So that's reason to think this early warning system might be critical to activate if we are going to design a vaccine" (AFP/Google, 10/18).


Reprinted with kind permission from kaisernetwork. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at kaisernetwork/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation.?  All rights reserved.


Our Recommendations:


•   Order Super Antiox GSE No Prescription
•   Buy Hydrochlorothiazide
•   Buy Lipothin Without Prescription

EntreMed Commences Phase 2 Study With MKC-1 In Pancreatic Cancer

EntreMed, Inc.
(Nasdaq: ENMD), a clinical-stage pharmaceutical company developing
therapeutics for the treatment of cancer and inflammatory diseases,
announced that it has commenced a multi-center Phase 2 clinical trial with
MKC-1 in patients with advanced pancreatic cancer. The primary objectives
of this study will be to determine the antitumor activity of
orally-administered MKC-1 in unresectable or metastatic pancreatic cancer
patients who have failed at least one prior chemotherapy regimen. The study
will also assess the safety, tolerability and overall median survival time
of pancreatic cancer patients treated with MKC-1. Massachusetts General
Hospital Cancer Center is the lead institution for the study and Eunice
Kwak, M.D., Ph.D., Assistant in Medicine, Tucker Gosnell Center for
Gastrointestinal Cancers, will serve as the principal investigator.


MKC-1 is a novel, orally-active cell cycle inhibitor with in vitro and
in vivo efficacy against a broad range of human solid tumor cell lines,
including multi-drug resistant cell lines. Prior preclinical studies have
demonstrated that MKC-1 has significant antitumor activity as both a single
agent and in combination with an approved epidermal growth factor/epidermal
growth factor receptor (EGF/EGFR) inhibitor in pancreatic cancer models.
MKC-1 has also demonstrated broad-acting antitumor effects, including tumor
growth inhibition or regression, in multiple preclinical models. MKC-1 has
been shown to inhibit mitotic spindle formation, prevent chromosome
segregation in the M-phase (mitosis) of the cell cycle, and induce
apoptosis.



Carolyn F. Sidor, M.D., M.B.A., EntreMed Vice President and Chief
Medical Officer, commented on the study, "Pancreatic cancer patients
continue to need more effective and better tolerated treatment options.
MKC-1 has shown good activity in preclinical testing against pancreatic
tumors, supporting its use in this patient population. Positive results
from this clinical trial will provide the basis for designing future
randomized Phase 2 studies. With this clinical trial initiation, we are now
evaluating MKC-1 as a single agent or in combination in patients with
pancreatic cancer, metastatic breast cancer, non- small cell lung cancer
(NSCLC), and leukemia."



About Pancreatic Cancer



Pancreatic cancer is the abnormal cell growth in the tissue of the
pancreas. The pancreas is an organ about six inches in length which is
located behind the stomach, next to the small intestine. The pancreas
produces enzymes that aide in the digestion and absorption of food. Unless
pancreatic cancer is detected early, it is difficult to control. At the
present time, there is no effective screening for pancreatic cancer and,
because the pancreas is hidden by other organs, it is difficult to
diagnosis. Pancreatic cancer is the fourth leading cause of cancer death in
the United States. The American Cancer Society estimates that approximately
37,000 Americans will be diagnosed with cancer of the pancreas in 2007,
resulting in approximately 33,000 deaths.
















About EntreMed



EntreMed, Inc. is a clinical-stage pharmaceutical company developing
therapeutic candidates primarily for the treatment of cancer and
inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in
multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle
regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a
novel tubulin-binding agent, is in Phase 1 studies in advanced cancers.
Panzem(R) is also in preclinical development for rheumatoid arthritis, and
ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical
development for cancer. EntreMed's goal is to develop and commercialize new
compounds based on the Company's expertise in angiogenesis, cell-cycle
regulation and inflammation -- processes vital to the treatment of cancer
and other diseases, such as rheumatoid arthritis. Additional information
about EntreMed is available on the Company's web site at entremed
and in various filings with the Securities and Exchange Commission.



Forward Looking Statements



This release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act with respect to the outlook
for expectations for future financial or business performance (including
the timing of royalty revenues and future R&D expenditures), strategies,
expectations and goals. Forward-looking statements are subject to numerous
assumptions, risks and uncertainties, which change over time.
Forward-looking statements speak only as of the date they are made, and no
duty to update forward-looking statements is assumed. Actual results could
differ materially from those currently anticipated due to a number of
factors, including those set forth in Securities and Exchange Commission
filings under "Risk Factors," including risks relating to the need for
additional capital and the uncertainty of additional funding; variations in
actual sales of Thalomid(R), risks associated with the Company's product
candidates; the early-stage products under development; results in
preclinical models are not necessarily indicative of clinical results,
uncertainties relating to preclinical and clinical trials; success in the
clinical development of any products; dependence on third parties; future
capital needs; and risks relating to the commercialization, if any, of the
Company's proposed products (such as marketing, safety, regulatory, patent,
product liability, supply, competition and other risks).


EntreMed, Inc.

entremed

Our Recommendations:


•   Buy Zithromax Without Prescription
•   Buy Hydrochlorothiazide
•   Order Bactrim No Prescription

The 45th Annual Meeting Of The American Society Of Clinical Oncology

The following are based on abstracts or posters to be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2, 2008.



Abstract # 9075, 8 a.m. to noon on Monday, June 1, 2009

Antiparasitic drug is promising in animal studies of metastatic melanoma



Seth J. Orlow, M.D., Ph.D., the Samuel Weinberg Professor of Pediatric Dermatology and chairman of the Ronald O. Perelman Department of Dermatology and professor of cell biology and pediatrics.



A drug used to treat parasitic infections shows early promise in animal studies as a potential treatment for metastatic melanoma. Researchers from NYU Langone Medical Center report that the orally administered drug, mebendazole, inhibited the growth and progression of human melanoma tumors grafted in mice. The researchers observed in the animals a 72 percent reduction in tumor volume, the inactivation of a key protein that normally promotes melanoma survival and a concomitant 81 percent increase in cancer cells that were programmed to die. The researchers are now planning a clinical trial to investigate the appropriate dosing of the drug, a first step toward assessing the drug's effectiveness in patients with metastatic melanoma.



Abstract # 9006, 1:30 p.m. on Saturday, May 30, 2009

MicroRNAs may aid in prognosis of metastatic melanoma



Eva Hernando-Monge, Ph.D., assistant professor of pathology

Iman Osman, M.D., associate professor of dermatology and urology and director of the Interdisciplinary Melanoma Cooperative Group

Miguel F. Segura, Ph.D., postdoctoral fellow



Ongoing research at the NYU Cancer Institute suggests that micoRNA - a genetic element that controls protein-coding genes - may be useful as a biomarker for melanoma. In the latest study, levels of a specific group of microRNAs were associated with longer survival among patients with metastatic melanoma and among those whose cancer has recurred after treatment. Researchers analyzed single-stranded RNA molecules in cancer tissue samples at various sites in the body, including the brain and lymph nodes, from 59 metastatic melanoma patients. Higher levels of 18 specific miRNAs were associated with surviving more than 18 months. The researchers are evaluating whether 10 of these co-called "protective" miRNAs identified in the study can help predict the likelihood of surviving 18 months after cancer recurrence and whether these miRNAS may help predict the aggressiveness of the disease in earlier stages of melanoma.



Abstract # 9044, 8 a.m. to noon on Monday, June 1, 2009

Blood-based marker may be tied to poor melanoma prognosis



Iman Osman, M.D., associate professor of dermatology and urology and director of the Interdisciplinary Melanoma Cooperative Group
















Higher levels of a protein found in the blood may be associated with a poor prognosis in melanoma patients. Researchers at the NYU Cancer Institute found that HU177, a connective tissue protein, was associated with a subset of melanoma patients with a poor prognosis. The study involved 209 patients whose serum levels of the protein were measured at the time of diagnosis. Thirty-eight of the 209 (18%) patients developed recurrences, and 34 of these patients subsequently died during the+ follow-up period of the study. Median follow-up time for survivors was 54.9 months, ranging from two to 81 months. The chances of staying free of cancer after a particular treatment, as well as the likelihood of survival over a certain period of time, were associated with higher serum levels of the protein. The correlation occurred even when other prognostic factors, such as tumor thickness and histology, were taken into account.



Abstract # 11034, Sunday, May 31, 2009, 2 p.m. to 6 p.m.

Overexpression of an oncogene linked to worse melanoma prognosis



Iman Osman, M.D., associate professor of dermatology and urology and director of the Interdisciplinary Melanoma Cooperative Group



Researchers at the NYU Cancer Institute present preliminary evidence that overabundant expression of an oncogene called Skp2 was associated with a worse melanoma prognosis. The activity of this gene was also linked to organs in the body where melanoma had spread. The study measured Skp2 protein levels in 122 metastatic melanoma specimens taken from patients' tissues. It found that increased Skp2 was associated with lower survival during a three-year period after recurrence.



Abstract # 11019, Sunday, May 31, 2009, 2 p.m. to 6 p.m.

Potential biomarker for early stage lung cancer



Jessica Donnington, M.D., assistant professor of cardiothoracic surgery



NYU Langone Medical Center researchers report that a protein in the blood appears to be a promising tool for monitoring early stage lung cancer. In a small study, they found higher levels of an extracellular structural protein called osteopontin (OPN) in patients with early stage non-small cell lung cancer compared to current or former smokers, and they also found that the levels decreased among patients who had undergone lung cancer surgery. The study involved 60 patients with early stage lung cancer, 56 current or former smokers, 78 patients with lung cancer advanced enough to be considered pre-operative and another matched group who had already undergone surgery. The researchers say the findings warrant further investigations of this biomarker in the early stages of this form of lung cancer.



Abstract #2017, Saturday, May 30, 2009. 8 a.m. to 1 p.m.

Drug may increase survival in brain cancer patients



Michael Gruber, M.D., clinical professor of neurology and neurosurgery

Shahzad Raza, M.D., clinical research associate in the department of radiation oncology

Ashwatha Narayana, M.D., associate professor of radiation oncology



Bevacizumab is a cancer treatment approved by the FDA to treat advanced or metastatic colorectal, lung, and breast cancers, and relapsed malignant glioblastoma, a form of brain cancer. A small study by researchers at NYU Cancer Institute suggests the drug may have a role in treating patients with newly diagnosed glioblastoma. The treatment, which inhibits tumor growth by blocking the formation of new blood vessels, was given to 24 glioblastoma patients who also received radiation and concomitant chemotherapy; another 31 patients received similar treatments but without bevacizumab. The group receiving bevacizumab lived longer during and after treatment without their disease worsening - half of the patients lived without their disease worsening a median of 12 months, compared to seven months in the non-bevacizumab group. One- and two-year overall survival rates were 85 percent and 50 percent, respectively, in the bevacizumab group compared to 74 percent and 22 percent in the other group. The researchers say that the results are encouraging and the drug merits testing in a phase III study.



Our Recommendations:


•   Buy Nexium Online Without Prescription
•   Order Spiriva Without Prescription
•   Order Allegra No Prescription
•   Order Lasix

Allsup Outlines Five Critical Issues For Caregivers Preparing To Take On Financial And Healthcare Responsibilities, USA

Each year millions of individuals suffer a sudden or progressive impairment that makes it difficult or impossible for them to make sound financial and healthcare decisions on their own, according to Allsup, which offers services that support the financial well-being and health of individuals with disabilities. Stepping in for these individuals are caregivers, generally family or friends who don't have professional financial consulting experience. In addition, these caregivers now are in the very serious role of making critical decisions for the individual they've agreed to care for.



"The most important thing caregivers can do is to educate themselves on their responsibilities once they've taken on this role," said Paul Gada, an attorney and personal financial planning director of the Allsup Disability Life Planning Center . "It's not easy and can be further complicated by the emotional involvement the caregiver often has with the person they're caring for, be it a spouse, parent, other close relative or friend.



"It's also important, however, that caregivers recognize they are not alone and that they seek help when they need it," Gada added.



Having committed to be a caregiver, there is a lot of work that will need to be done. Following, Allsup outlines five crucial first steps.



Secure power of attorney



A power of attorney for property provides a caregiver the legal authority to make decisions about and exercise control of various assets and transactions. A healthcare power of attorney, directive or proxy allows an individual to designate someone to make decisions about their healthcare, including carrying out an individual's wishes about whether or not to use artificial life support (sometimes provided for separately in a living will document).



Most state governments and state bar associations offer a statutory template of these forms that can be pulled from their Web sites. Many hospitals and healthcare organizations also can provide individuals with the health-related forms.



While someone can designate the power of attorney for financial matters to one person and healthcare power of attorney to another, it's often simpler and avoids conflicts to have one person take on both roles.



"Inevitably, when you begin talking about someone's healthcare, financial matters come into play. So you want to designate someone you can trust who will be able to look at the whole picture," said Gada.



Healthcare power of attorney forms generally follow a similar format. However, a power of attorney for property and finances can be set up in various ways. These include:



- A durable power of attorney. This is effective immediately and remains in effect should the grantor (the person that is granting power of attorney) become disabled. It allows the agent (the individual the grantor has designated to act on his or her behalf) to make decisions about property and finances as outlined in the power of attorney document without the grantor's advanced approval.
















- A springing power of attorney. This only becomes effective if and when a person becomes disabled. Only then can the agent begin making decisions about the grantor's property and finances.



- A nondurable power of attorney. This limits the agent's authority to a specific situation or type of legal action for a limited time period, and it ceases to be effective should the grantor become disabled. It is commonly used for buying or selling real estate or allowing an agent to deposit or withdraw funds from the grantor's bank account.



Some individuals may fear they are giving up control by granting an agent durable power of attorney as the agent can immediately take control and begin making decisions. However, a springing power of attorney can present a problem if there is a disagreement between healthcare providers and family members regarding when the individual granting power of attorney became disabled or incompetent.



"As a caregiver with power of attorney, you are acting on another person's behalf," said Gada. "You want to make sure that you have a very clear understanding of what the individual you are caring for wants and that you truly are committed to acting in their best interest."



Gather and organize records



Caregivers should make certain that they have a copy of any power of attorney and living will, plus have secured access to other important legal and medical documents, including the individual's will or trust documents.



Other important financial information to gather includes:



??? Bills, including utilities, household maintenance payments, medical fees, etc.

??? Deeds, mortgage papers and ownership statements

??? Loan agreements

??? Medical records

??? Stock and bond certificates and statements

??? Pension, 401(k) and other retirement benefit statements

??? Bank and brokerage account information

??? Insurance policies, including long-term disability, healthcare, home, auto, etc.

??? Social Security payment information if Social Security or Social Security disability already has been secured

??? Pay stubs if the individual was working prior to the impairment

??? State and federal income tax returns



"Just as you do with your own financial records, as a caregiver you want to set up a system so that you can keep track of all the important documents of the individual for whom you are caring. Remember, you really are stepping into their shoes. You are responsible for making sure you know where things are and what needs to be done when," said Gada.



Create a financial profile and budget



The caregiver needs to understand the individual's financial circumstances. This means getting a handle on the resources available, or assets (e.g., home, investments, life insurance contracts, etc.) and liabilities (e.g., loans, mortgage, credit card debt, etc.).



Also, the caregiver likely will need to establish a monthly budget. This requires understanding income (e.g., from a long-term disability insurance policy, Social Security, investments or other resources) and expenses. As with any budget, this will need to be adjusted as circumstances change, but it's an important roadmap for ensuring that assets are available to support the individual, or recognizing where there are shortfalls so additional resources can be sought if possible.



"Many working adults don't set up monthly budgets. So long as the money coming in is far more than the money going out or needed for savings, this lack of planning can work," Gada said. "But when you're dealing with an individual that has a disability that is likely increasing their healthcare costs and keeping them from ever returning to full-time work, good planning is essential."



Depending on the individual's resources, the caregiver may want to consult with a professional financial advisor. Various financial software and online tools also can help caregivers determine a budget and monitor income and expenses, including free resources offered as part of Allsup's Financial Matters site.



Identify income resources



An individual with a severe disability generally will be relying on insurance payments for all or part of their future income. Approximately three in 10 workers is covered by a private long-term disability policy.



A caregiver should determine if the individual they are caring for has a long-term disability policy and, if so, what the qualifications and restrictions are for collecting on the policy. Examples include how soon the policy begins offering income, offsets to that income and when the policy expires (in some cases at age 65). Also, some policies include a Social Security rider, which requires that the individual apply for Social Security Disability Insurance (SSDI) in order to comply with the long-term disability insurer's requirements.



Most individuals who have worked are eligible for SSDI. To qualify, a person must have worked and paid into the program for five of the last 10 years; been disabled before reaching full-retirement age (65-67) and meet Social Security's definition of disability. The Social Security Administration (SSA) uses a process called sequential evaluation to determine who receives benefits.



Any caregiver responsible for securing SSDI benefits should understand that it's a complex and time-consuming process and can take several years to complete. Organizations like Allsup, however, can facilitate the SSDI application process and ensure the individual begins receiving SSDI benefits as quickly as possible.



"Two-thirds of SSDI applications are rejected and the average time it now takes, from initial application through appeals, to get an award is two to four years. Given all the responsibilities a caregiver has, getting help from a representative reduces the burden substantially," said Gada.



Determine health insurance coverage



If the individual was employed immediately before becoming disabled, the caregiver may look into helping him or her secure COBRA coverage. COBRA coverage can continue for up to 18 months after employment ends. This may be extended by an additional 11 months if an individual is awarded SSDI benefits.



"While these plans can be costly, they can be an essential financial planning component for individuals unable to get any other insurance and facing mounting healthcare costs while awaiting Medicare eligibility," said Gada.



Caregivers also need to be aware that after receiving SSDI benefits for 24 months, an individual - regardless of their age - is eligible for Medicare, including hospital, medical benefits and prescription drug plans. Just as important is understanding the different options available and which plans are best based on the individual's particular circumstances.



"Not all Medicare plans are created equal and people often opt for the traditional plan thinking it's the 'safe' choice. But for people with disabilities, Medicare Advantage plans often are the optimal choice: you can't be turned away for coverage due to a pre-existing condition, they usually cost less than a traditional Medicare and supplemental plan combined, and most Medicare Advantage plans include prescription drug coverage," explained Gada.



About Allsup


Allsup, Belleville, Ill., is a leading nationwide provider of financial and healthcare related services to people with disabilities. Founded in 1984, Allsup has helped more than 100,000 people receive their entitled Social Security Disability Insurance and Medicare benefits. Allsup employs more than 500 professionals who deliver services directly to consumers and their families, or through their employers and long-term disability insurancecarriers.


Allsup

Our Recommendations:


•   Buy Zyban Online
•   Order Cipro Online
•   Order Acomplia Without Prescription
•   Order Super Antiox GSE
•   Purchase Zithromax No Prescription